- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03111316
Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening
Combined Use of the Controlled Release Dinoprostone Insert and Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening and Labor Induction in Term Women: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Those who provide informed consent will be allocated by an online randomization system either to placement of a transcervical Foley catheter and an intravaginal dinoprostone controlled release insert or a Foley catheter alone. Randomization will be stratified by parity (nulliparous or parous).
In both study groups, the balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension. Also in both groups, the Foley catheter will be removed if any of the following occurs: 1) expulsion, 2) fetal heart rate tracing mandating evaluation for membrane rupture and placement of internal monitors, 3) spontaneous membrane rupture, or 4) if 12 hours has elapsed since placement. The dinoprostone insert will be removed if: 1) the fetal heart rate tracing mandates evaluation for membrane rupture and placement of internal monitors, 2) tachysystole develops (more than 5 contractions per 10 minutes averaged over 30 minutes, 3) spontaneous membrane rupture, or 4) 12 hours has elapsed since placement. Though these are the criteria for insert removal, in keeping with the pragmatic design of this trial, the decision regarding removal will be left to the discretion of the attending physician.
Women will remain recumbent for 30 minutes after agent placement and, except for trips to the restroom, will undergo continuous monitoring of uterine contractions and fetal heart rate. Oxytocin, according to standard intravenous protocol, will be allowed only after removal of cervical ripening agent(s). After specified cervical ripening, labor management will be at the discretion of the attending obstetrician, in keeping with the pragmatic nature of the study design.
Antibiotics will be administered if indicated for prophylaxis against early-onset neonatal infection with group B streptococci or for treatment of chorioamnionitis. Cesarean delivery will be performed, per the discretion of the attending obstetrician, for standard maternal or fetal indications.
Medical records will be reviewed no less than 30 days after delivery. Demographic, intrapartum, and outcome data will be entered into a computerized database.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- The University of Oklahoma Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cervix ≤2 cm dilated; if 2 cm, <80% effaced
- Gestational age 37 weeks or more
- Singleton gestation
- Cephalic presentation
- Live fetus
Exclusion Criteria:
- Contractions more frequent than every 5 minutes
- Premature rupture of membranes
- Prior uterine incision
- Temperature 38C or higher
- Fetal anomalies
- Placenta previa
- Suspected abruption or undiagnosed bleeding more than spotting
- Fetal heart rate tracing prior to enrollment with no more than minimal variability, late decelerations, or more than two variable decelerations
- HIV infection
- Allergy to either latex or dinoprostone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Foley Catheter & Dinoprostone Insert
transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
|
Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape.
Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert.
An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated.
The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Other Names:
The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
|
Other: Foley Catheter Alone
a Foley catheter alone
|
The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Median Times From Placement of Foley Catheter to Vaginal Delivery
Time Frame: 48 hours
|
median time estimation for use of dinoprostone and foley catheter and foley catheter alone
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Evaluate the Proportion of Patients That Delivered by 12 Hours and Proportion of Patients Delivered by 24 Hours
Time Frame: 24 hours
|
To evaluate the proportion of patients that delivered vaginally by 12 hours and proportion of patients delivered vaginally by 24 hours.
|
24 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rodney K Edwards, MD, The University of Oklahoma Health Sciences Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ferring
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Induction of Labor
-
Rambam Health Care CampusNot yet recruitingInduction of Labor
-
Duke UniversityCompleted
-
Ochsner Health SystemNorthwell HealthTerminatedInduction of LaborUnited States
-
Brigham and Women's HospitalCompleted
-
Aultman Health FoundationCompletedInduction of LaborUnited States
-
Dina Yahia MansourUnknown
-
HaEmek Medical Center, IsraelCompletedSingle Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable CervixInduction of LaborIsrael
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Holy Family Hospital, Nazareth, IsraelRecruitingInduction of LaborIsrael
-
Kazakhstan's Medical University "KSPH"Asfendiyarov Kazakh National Medical UniversityActive, not recruitingInduction of LaborKazakhstan
Clinical Trials on Cervidil 10 MG Vaginal Insert
-
Ferring PharmaceuticalsCompletedLabor, Induced | Cervical RipeningUnited States, Canada
-
Intermountain Health Care, Inc.Ferring PharmaceuticalsTerminatedInduction of Labor Affected Fetus / NewbornUnited States
-
CONRADCompletedVaginal DiseasesUnited States
-
EndoCeutics Inc.CompletedHypoactive Sexual Desire DisorderUnited States, Canada
-
EndoCeutics Inc.AMAG Pharmaceuticals, Inc.WithdrawnHypoactive Sexual Desire Disorder (HSDD)United States
-
Ferring PharmaceuticalsCompletedCervical Ripening | Labor InductionUnited Kingdom
-
Eastern Virginia Medical SchoolUniversity of Pittsburgh; United States Agency for International Development... and other collaboratorsRecruitingSafety IssuesUnited States, Kenya, South Africa
-
Ferring PharmaceuticalsCompletedInduction of Labor | Cervical Ripening | Reducing Time to Vaginal DeliveryUnited States
-
Wolfson Medical CenterUnknown
-
CONRADUnited States Agency for International Development (USAID); Eastern Virginia...Completed